Tuesday, April 21, 2009

AIDS and HIV Vaccines

AIDS or acquired immunodeficiency Syndrome is caused by human immunodeficiency virus (HIV). The World Health Organization (WHO) is an International Organization associated with the community health programs throughout the world and it is the reward of concerted efforts that the diseases like smallpox and polio have completely been eradicated through vaccination. Now the worldwide focus is on the development of an effective vaccine to control the spread of AIDS and providing prophylaxis to health professionals. An ideal HIV vaccine would be the one which could mount a good humoral and cell mediated immune response both locally and systemically. HIV is an enveloped virus that contains two copies of genomic ribonucleic acid (RNA). There is a glycoprotein of 120 kD molecular weight commonly known as gp120, through which the virus binds to the cellular receptors at the surface of T-helper lymphocytes or CD4+ cells. The binding of virus to the CD4 receptor in association with chemokine co-receptor causes a dynamic change in gp120 and further activates trans-membrane protein gp41. These changes cause fusion of HIV envelope to the cell membrane of CD4+ cell and further make way for the entry of virus into the cytoplasm of CD4+ cell, replicate there, destroy cell and infect new cells.


Experimental studies in animals have shown that a considerable amount of T-cell response can be induced with HIV vaccines thereby limiting the viral RNA levels in plasma and minimizing the destruction of CD4+ T-cells. The survival of CD4+ T-cells through vaccination might help control infection and prolong disease-free survival of immunized person. The HIV vaccine capable of controlling the viral replication may also reduce the secondary transmission since the progression of secondary transmission is directly related to the plasma viral load. The oldest procedure of vaccine development has been tried wherein live attenuated viruses are used as vaccine but could not be put to the practice in case of HIV vaccine due to danger of infection if the virus particle were not completely killed or attenuated. Novel strategies are being used wherein certain immunogenic viral peptides (non-infectious and genetically engineered) have been tried and put to clinical trials. HIV vaccines developed on the guidelines of viral vectors containing vaccines and DNA vaccines are under way of active clinical trials. The vaccine war is going on against HIV.

Saturday, April 18, 2009

Anti-Retroviral Drugs for Treatment and Prophylaxis

There are over a dozen anti-retroviral drugs duly approved for treatment of HIV-1 infection and for optimal prophylaxis against the virus. Anti-retroviral drugs include HIV-1 protease inhibitors, non nucleoside reverse transcriptase inhibitors (NNRTIs) and fusion inhibitors (HIV entry inhibitors). At present combination drug therapy is used to thrash the dynamics of HIV-1 replication. The four main classes of anti viral agents are: (1) Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs and NtRTIs), (2) Non nucleoside reverse transcriptase inhibitors (NNRTIs), (3) Protease inhibitors (PIs) and (4) HIV entry inhibitors.


Nucleoside reverse transcriptase inhibitors (NRTIs) available are: Zidovudine (AZT/ZDV), Stavudine (d4T), Lamivudine (3TC), Didanosine (ddI), Zalcitabine (ddC), Abacavir (ABC) and Emtricitabine (FTC).


Nucleotide reverse transcriptase inhibitor (NtRTI) available is: Tenofovir (TDF).


Non nucleoside reverse transcriptase inhibitors (NNRTIs) available are: Nevirapine (NVP), Efavirenz (EFV), Delavirdine (DLV) and Etravirine.


Protease inhibitors (PIs) available are: Saquinavir (SQV), Ritonavir (RTV), Nelfinavir (NFV), Amprenavir (APV), Indinavir (INV), Lopinavir/Ritonavir (LPV), Fosamprenavir (FPV), Atazanavir (ATV) and Tipranavir (TPV).


HIV entry inhibitors (Fusion inhibitors) available are: Enfuviritide (T-20) and CCR5 entry inhibitors.


Acquired immunodeficiency Syndrome or AIDS is caused by human immunodeficiency virus (HIV). HIV is an enveloped virus that contains two copies of genomic ribonucleic acid (RNA). There is a glycoprotein of 120 kD molecular weight commonly known as gp120, through which the viruses bind to the cellular receptors at the surface of T-helper lymphocytes or CD4+ cells. The binding of virus to the CD4 receptor in association with chemokine co-receptor causes a dynamic change in gp120 and further activates trans-membrane protein gp41. These changes cause fusion of HIV envelope to the cell membrane of CD4+ cell and further make way for the entry of virus into the cytoplasm of CD4+ cell. The main receptors used by HIV-1 are chemokine receptors CCR5 and CXCR4. It has been resolved through the assessment of amino acid sequences of different HIV-1 strains that there are five variable (V1-V5) and four constant (C1-C4) regions in gp120. The expression of CCR5 or CXCR4 on the surface of CD4+ target cells (T-helper lymphocytes) defines their susceptibility to infection by corresponding HIV-1 strain. The use of specific receptors by viruses for infecting the target cells determines the virus cell tropism. The dual tropic viral strains can use both the receptors at the surface of CD4+ target cells. It is well established now that R5 viruses remain present in approximately 50-60% of individuals who progress to AIDS, whereas remaining 40-50% of individuals switch to X4 viruses with the progression of the disease and show a decline in the count of CD4+ target cells. The mutations in viruses confer them resistance to CCR5 treatment in the absence of co-receptor switch. HIV entry inhibitor compounds have been gaining importance as therapeutic agents for the treatment and post exposure prophylaxis against HIV infection. The aim of HIV therapy is to suppress the viral infection to achieve the disease free prolonged survival and this can not be achieved with monotherapy only due to complex life cycle of HIV.


HAART Therapy


The most effective HIV therapy is the highly active anti-retroviral therapy (HAART) wherein anti-retroviral agents are administered in combination of different drug classes. Generally HAART is any combination regimen designed to achieve the goal of complete virus suppression and these regimens comprise a minimum of three drugs. NNRTI based regimen comprises two NRTI or NtRTIs plus one NNRTI. PI based regimen comprises two NRTI or NtRTIs plus one or more PIs. Monotherapy is restricted to the prevention of perinatal transmission of HIV. Zidovudine (ZDV or AZT) and nevirapine (NVP) are generally used drugs for the monotherapy. The indications for HAART are history of AIDS-defining illness with CD4+ cell counts <350/µl or pregnant women without consideration for CD4+ cell count. Persons with HIV-associated nephropathy and persons co-infected with hepatitis virus-B (HBV) are considered fit cases for initiation of HAART.

AIDS and HIV Entry Inhibitors’ Target Action

Acquired immunodeficiency Syndrome or AIDS is caused by human immunodeficiency virus (HIV). HIV is an enveloped virus that contains two copies of genomic ribonucleic acid (RNA). There is a glycoprotein of 120 kD molecular weight commonly known as gp120, through which the virus binds to the cellular receptors at the surface of T-helper lymphocytes or CD4+ cells. The binding of virus to the CD4 receptor in association with chemokine co-receptor causes a dynamic change in gp120 and further activates trans-membrane protein gp41. These changes cause fusion of HIV envelope to the cell membrane of CD4+ cell and further make way for the entry of virus into the cytoplasm of CD4+ cell. The virus entry inhibitors sabotage the ability of gp41 to mediate fusion of viral and cellular envelopes. HIV entry inhibitor drugs are of first choice after exposure to virus and are newer drugs in the scenario of HIV therapy. Currently, most regimens of HIV therapy are combinations of inhibitors of two viral enzymes: reverse transcriptase and protease. HIV entry inhibitors are of great interest because of their activity against multi-drug resistant viruses.

The brief mechanism of HIV entry into T-helper lymphocytes or CD4+ cells has been cited above. The main receptors used by HIV-1 are chemokine receptors CCR5 and CXCR4. It has been resolved through the assessment of amino acid sequences of different HIV-1 strains that there are five variable (V1-V5) and four constant (C1-C4) regions in gp120. The expression of CCR5 or CXCR4 on the surface of CD4+ target cells (T-helper lymphocytes) defines their susceptibility to infection by corresponding HIV-1 strain. The use of specific receptors by viruses for infecting the target cells determines the virus cell tropism. The dual tropic viral strains can use both the receptors at the surface of CD4+ target cells. The HIV entry inhibitor compounds could be targeting the inhibition at different stages of virus entry such as:


  1. The attachment inhibitor: Sulfated polysaccharides or polyanions such as dextran sulfate (dextran-2-sulfate or D2S) and heparin have been shown to inhibit binding of V3 loop antibodies to HIV-1 gp120 in-vitro.

  2. Inhibitors of gp120-CD4 interaction: The currently available inhibitors of gp120-CD4 interaction are PRI 542 (CD4 - IgG2), TNX 355, and BMS 488043 antibodies/molecules. PRI 542 (CD4 - IgG2) is a tetravalent antibody and has passed clinical trials. TNX 355 is a monoclonal antibody (humanized) against the domain-2 of human CD4. BMS 488043 is a small molecule and blocks the entry of virus by preventing the binding of gp120 to CD4 receptors on CD4+ target cells.

  3. Co-receptor Antagonists: Some new molecules have been tried as antagonists to CXCR4 and CCR5 but abandoned due to cardiac abnormalities and heart conduction abnormalities like prolonged QT intervals. CCR5 is the co-receptor mainly used by HIV for its transmission; so many drugs have been enlisted for targeting CCR5.

It is well established now that R5 viruses remain present in approximately 50-60% of individuals who progress to AIDS, whereas remaining 40-50% of individuals switch to X4 viruses with the progression of the disease and show a decline in the count of CD4+ target cells. The mutations in viruses confer them resistance to CCR5 treatment in the absence of co-receptor switch. HIV entry inhibitor compounds have been gaining importance as therapeutic agents for the treatment and post exposure prophylaxis against HIV.

Friday, March 20, 2009

Evolution of Antimalarial Drugs

The effectiveness of the antimalarial drugs may differ with the species and stage of parasite and the parasite load in the liver and blood circulation. The malaria is an intracellular protozoan infection, endemic in tropical and subtropical countries. Four species of the protozoal parasite Plasmodium cause all infections in human beings and these are: Plasmodium vivax, Plasmodium malariae, Plasmodium ovale and Plasmodium falciparum. The parasites are inoculated into the human host by blood sucking female anopheline mosquitoes. The sporozoites from the infected mosquito reach the liver and develop into tissue schizonts. These tissue schizonts then rupture, form free merozoites and invade erythrocytes or red blood cells (RBCs) and develop as erythrocytic schizonts and lead to rupture of RBCs. Antimalarial drugs have undergone a great deal of evolution and at present there are many classifications of antimalarial drugs depending on the stages of malarial parasites in the liver and erythrocytes, on the bases of chemical groups or clinical effectiveness of the drugs.


If we look at the chemical groups of antimalarial drugs the Cinchona alkaloid or Quinine and Quinidine were the very first drugs and there after 4-aminoquinoline (Chloroquine and Amodiaquine), 8-aminoquinoline (Primaquine and Bulaquine), Quinoline-Methanol (Mefloquine) and Biguanides (Proguanil and Chlorproguanil) were developed. Diaminopyrimidines (Pyrimethamine), Sulfonamides (Sulfadoxine and Dapsone), Tetracyclines (Tetracycline and Doxycycline) and Aminoalcohols (Halofantrine and Lumefantrine) are other effective antimalarial drugs. Chloroquine has been used extensively for the treatment and prevention of malaria. It has considerable efficacy for the treatment of Plasmodium vivax, Plasmodium malariae and Plasmodium ovale infections, however, widespread resistance has been seen against Plasmodium falciparum infection. Artemisinin, Artemether, Artemotil and Atovaquone could be called newer antimalarial drugs. Artemisinin or Qinghaosu is a sesquiterpene lactone extracted from the leaves of Artemisia annua known as Sweet Wormwood in China. The extract of the leaves of Artemisia annua or Sweet Wormwood has been used in China for over a thousand years for the treatment of fever. Antifolate combinations like sulfadoxine pyrimethamine and sulfalene pyrimethamine are more safe drugs but are known to have longer elimination half life.


In terms of clinical effect on various stages of malarial parasites, the effectiveness of antimalarial drugs is contested for prophylaxis and anti-parasite activity. Effective suppressive prophylaxis has been documented with chloroquine, mefloquine, proguanil and doxycycline as these are schizonticidal drugs. Proguanil and primaquine are best known for causal prophylaxis as these drugs effectively kill the hepatic stages of the parasite. Quinine, chloroquine, primaquine and artemisnins are established gametocidal drugs also. Sulfonamides (sulfadoxine and dapsone) and aminoalcohols (halofantrine and lumefantrine) are also used in the treatment of malaria but are more toxic drugs. The drug toxicity may lead to acute hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Consult your physician for the diagnosis and treatment of malaria.

Wednesday, March 18, 2009

What Could Lead to Drug Addiction ?

Experimentation with psychotropic drugs for fun and elated feelings could activate certain receptors of our brain to such an extent that one would feel depressed without taking a particular drug. When a person starts taking a psychotropic drug, he/she enjoys the drug's euphoric effects. Repeated desire for elevated mood and a kick makes one addict for ever. The drug addiction is mostly unintentional as a person who begins with casual use of a drug does not know that the substance could become his/her daily desire. The drug associated altered neurophysiology leads to drug dependence. The drug related release of neurotransmitters may alter the ultrastructural architecture of neurons at a later stage. Some drugs may lock into some neurons and act like a pump and extensively stimulate the neurons to release more and more neurotransmitters. There exists a natural balance of neurotransmitters under the normal conditions of neurophysiology, but certain drugs may block reabsorption or reuptake of neurotransmitters, leading to behavioral changes altered physiology. The drug adiction is a complex brain disease. Despite the fact that the high effects of a drug are short term phenomenon, one finds it difficult to quit the habit. The compulsive and uncontrollable craving for a psychotropic drug leads to such a behavioral change that one would ignore all the moral values of the life and society to acquire a drug. The habitual use of a neurostimulator or psychotropic drug severely affects the neurophysiology and leads to drug addiction.